Metformin in women with type 2 diabetes in pregnancy (MiTy): a multi-center randomized controlled trial

@inproceedings{Feig2016MetforminIW,
  title={Metformin in women with type 2 diabetes in pregnancy (MiTy): a multi-center randomized controlled trial},
  author={Denice S Feig and Kellie E Murphy and Elizabeth V Asztalos and George Tomlinson and Johanna Sanchez and Bernard Zinman and Arne Ohlsson and Edmond A. Ryan and Ivan George Fantus and Anthony B. Armson and Lorraine L. Lipscombe and Jon F. R. Barrett and George D Carson and Suzanne E. Williams and Sheila J Kelly and Heather Clark and Diane Donat and Shital Gandhi and Barbara Cleave and Michele Strom and L E Donovan and Carolyn Oldford and Catherine Young and Brenda Galway and Minnie Parsons and Ariane Godbout and Mich{\`e}le Mahone and Florence Weber and Marie-Jos{\'e}e B{\'e}dard and Bi Lan Wo and Sylvie Daigle and Amir Hanna and Maria Wolfs and Leanne De Souza and Robyn L. Houlden and Adriana Breen and Tina Kader and Luca Cefis and Erin Keely and Josee Champagne and Jennifer A. Klinke and Julie C. Lee and Peter Subrt and Francina Carr and Sharon Neu Young and Sarah Kwong and Heather L. Rylance and H{\'e}l{\`e}ne Long and Julie Lambert and Julia Lowe and Anna Rogowsky and Susan Jackson and Sora M Ludwig and Laurie Slater and L Anick B{\'e}rard and David P. McIntyre and Anne Tremellen and Ruth McManus and Sara M Meltzer and Natasha Garfield and Shari Segal and David Miller and Karen E Coles and Carol Fergusson and Jill Newstead-Angel and Judy Brandt and Thomas P P Ransom and Darlene M Baxendale and Evelyne Rey and Diane Francoeur and Sophie Perreault and Dory A. Sample and D. Thompson and Sharon M. Thompson and John Stanley Weisnagel and Camile Lambert and V Julien and Marie-Christine Dub{\'e} and Louise Rheaume and Afshan Zahedi and Grace Y Lee and Krystyna Szwiega and Asma Qureshi and Siobhan Maeve Tobin},
  booktitle={BMC pregnancy and childbirth},
  year={2016}
}
BACKGROUND The incidence of type 2 diabetes in pregnancy is rising and rates of serious adverse maternal and fetal outcomes remain high. Metformin is a biguanide that is used as first-line treatment for non-pregnant patients with type 2 diabetes. We hypothesize that metformin use in pregnancy, as an adjunct to insulin, will decrease adverse outcomes by reducing maternal hyperglycemia, maternal insulin doses, maternal weight gain and gestational hypertension/pre-eclampsia. In addition, since… CONTINUE READING